APCS and lupus nephritis: Further SAP gene administration in the early stage of SLE disease could reversed lupus nephritis via reduced pathogenic anti-dsDNA antibody production, while in the late stage of disease, SAP gene treatment alleviated proteuria and lupus nephritis via reducing the infiltration of leukocytes and the production of inflammatory markers besides decreasing the levels of anti-dsDNA antibodies.